Cell fusion and dendritic cell-based vaccines

Cell Fusions: Regulation and Control

Volumn , Issue , 2011, Pages 315-350

  Gong, Jianlin ^a   Koido, Shigeo ^b  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Antitumor immunity; cancer; cell cell fusion; dendritic cell; fusion cell vaccine; immune therapy

Indexed keywords

EID: 84900089303     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-90-481-9772-9_15     Document Type: Chapter

References (183)

1. Ahkong QF, Baldwin JM, O'Reilly R et al (1994) Interactions between metal ions and poly(ethylene glycol) in the fusion of human erythrocytes. Mol Membr Biol 11:171-179
2. Ahkong QF, Lucy JA (1986) Osmotic forces in artificially induced cell fusion. Biochim Biophys Acta 858:206-216
3. Akasaki Y, Kikuchi T, Homma S et al (2001) Antitumor effect of immunizations with fusions of Dendritic and Glioma cells in a mouse brain tumor model. J Immunother 24:106-113
4. Avigan D, Vasir B, Gong J et al (2004) Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses. Clin Cancer Res 10:4699-4708
5. Avigan DE, Vasir B, George DJ et al (2007) Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma. J Immunother 30:749-761
6. Bateman A, Bullough F, Murphy S et al (2000) Fusogenic membrane glycoproteins as a novel class of genes for the local and immune-mediated control of tumor growth. Cancer Res 60:1492-1497
7. Bateman AR, Harrington KJ, Kottke T et al (2002) Viral fusogenic membrane glycoproteins kill solid tumor cells by nonapoptotic mechanisms that promote cross presentation of tumor antigens by dendritic cells. Cancer Res 62:6566-6578
8. Behrens G, Li M, Smith CM et al (2004) Helper T cells, dendritic cells and CTL Immunity. Immunol Cell Biol 82:84-90
9. Bennett SR, Carbone FR, Karamalis F et al (1997) Induction of a CD8+ cytotoxic T lymphocyte response by cross-priming requires cognate CD4+ T cell help. J Exp Med 186:65-70
10. Berard F, Blanco P, Davoust J et al (2000) Cross-priming of naive CD8 T cells against melanoma antigens using dendritic cells loaded with killed allogeneic melanoma cells. J Exp Med 192: 1535-1544
11. Bischoff R, Eisert RM, Schedel I et al (1982) Human hybridoma cells produced by electro-fusion. FEBS Lett 147: 64-68
12. Cao X, ZhangW,Wang J et al (1999) Therapy of established tumour with a hybrid cellular vaccine generated by using granulocyte-macrophage colony-stimulating factor genetically modified dendritic cells. Immunology 97:616-625
13. Celluzzi CM, Falo LD Jr (1998) Physical interaction between Dendritic cells and tumor cells results in an immunogen that induces protective and therapeutic tumor rejection. J Immunol 160:3081-3085
14. Celluzzi CM, Mayordomo JI, Storkus WJ et al (1996) Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. J Exp Med 183:283-287
15. Chaux P, Vantomme V, Stroobant V et al (1999) Identification of MAGE-3 epitopes presented by HLA-DR molecules to CD4(+) T lymphocytes. J Exp Med 189:767-778
16. Chen EH, Olson EN (2004) Towards a molecular pathway for myoblast fusion in Drosophila. Trends Cell Biol 14:452-460
17. Chomez P, De Backer O, Bertrand M et al (2001) An overview of the MAGE gene family with the identification of all human members of the family. Cancer Res 61:5544-5551
18. Condon C,Watkins SC, Celluzzi CM et al (1996) DNA-based immunization by in vivo transfection of dendritic cells. Nature Med 2:1122-1128
19. Coughlin CM, Wysocka M, Kurzawa HL et al (1995) B7-1 and interleukin 12 synergistically induce effective antitumor immunity. Cancer Res 55:4980-4987
20. Das D, Suresh MR (2005) Producing bispecific and bifunctional antibodies. Methods Mol Med 109:329-346
21. Davidson RL, Gerald PS (1976) Improved techniques for the induction of mammalian cell hybridization by polyethylene glycol. Somatic Cell Genet 2:165-176
22. de StGroth SF, Scheidegger D (1980) Production of monoclonal antibodies: Strategy and tactics. J Immunol Methods 35:1-21
23. Dranoff G, Jaffee E, Lazenby A et al (1993) Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-Tumor immunity. Proc Natl Acad Sci USA 90:3539-3543
24. Du YC, Lin P, Zhang J et al (2006) Fusion of CpG-ODN-stimulating dendritic cells with Lewis lung cancer cells can enhance anti-Tumor immune responses. Tissue Antigens 67:368-376
25. Ebert O, Shinozaki K, Kournioti C et al (2004) Syncytia induction enhances the oncolytic potential of vesicular stomatitis virus in virotherapy for cancer. Cancer Res 64:3265-3270
26. Fabre JW (2001) The allogeneic response and tumor immunity. Nat Med 7:649-652
27. Finn OJ (2003) Cancer vaccines: Between the idea and the reality. Nat Rev Immunol 3:630-641
28. Ford WL, Atkins RC (1973) The proportion of lymphocytes capable of recognizing strong transplantation antigens in vivo. Adv Exp Med Biol 29:255-262
29. Ford WL, Simmonds SJ, Atkins RC (1975) Early cellular events in a systemic graft-vs.-host reaction. II. Autoradiographic estimates of the frequency of donor lymphocytes which respond to each Ag-B-determined antigenic complex. J Exp Med 141:681-696
30. Frye LD, EdidinM(1970) The rapid intermixing of cell surface antigens after formation of mousehuman heterokaryons. J Cell Sci 7:319-335
31. Furusawa M, Nishimura T, Yamaizumi M et al (1974) Injection of foreign substances into single cells by cell fusion. Nature 249:449-450
32. Gabrijel M, Repnik U, Kreft M et al (2004) Quantification of cell hybridoma yields with confocal microscopy and flow cytometry. Biochem Biophys Res Commun 314:717-723
33. Galea-Lauri J, Darling D, Mufti G et al (2002) Eliciting cytotoxic T lymphocytes against acute myeloid leukemia- derived antigens: Evaluation of dendritic cell-leukemia cell hybrids and other antigen-loading strategies for dendritic cell-based vaccination. Cancer Immunol Immunother 51:299-310
34. Galfre G, Howe SC, Milstein C et al (1977) Antibodies to major histocompatibility antigens produced by hybrid cell lines. Nature 266:550-552
35. Goddard RV, Prentice AG, Copplestone JA et al (2003) In vitro dendritic cell-induced T cell responses to B cell chronic lymphocytic leukaemia enhanced by IL-15 and dendritic cell-B-CLL electrofusion hybrids. Clin Exp Immunol 131:82-89
36. Gong J, Apostolopoulos V, Chen D et al (2000c) Selection and characterization of MUC1-specific CD8+ T cells from MUC1 transgenic mice immunized with dendritic-carcinoma fusion cells. Immunology 101:316-324
37. Gong J, Avigan D, Chen D et al (2000a) Activation of antitumor cytotoxic T lymphocytes by fusions of human Dendritic cells and breast carcinoma cells. Proc Natl Acad Sci USA 97:2715-2718
38. Gong J, Chen D, Kashiwaba M et al (1997b) Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nat Med 3:558-561
39. Gong J, Chen D, Kashiwaba M et al (1998) Reversal of tolerance to human MUC1 antigen in MUC1 transgenic mice immunized with fusions of dendritic and carcinoma cells. Proc Natl Acad Sci USA 95:6279-6283
40. Gong J, Chen L, Chen D et al (1997a) Induction of antigen-specific antitumor immunity with adenovirus- Transduced dendritic cells. Gene Ther 4:1023-1028
41. Gong J, Koido S, Chen D et al (2002) Immunization against murine multiple myeloma with fusions of dendritic and plasmacytoma cells is potentiated by interleukin 12. Blood 99:2512-2517
42. Gong J, Koido S, Kato Y et al (2004) Induction of anti-leukemic cytotoxic T lymphocytes by fusion of patient-derived dendritic cells with autologous myeloblasts. Leuk Res 28:1303-1312
43. Gong J, Nikrui N, Chen D et al (2000b) Fusions of human ovarian carcinoma cells with autologous or allogeneic dendritic cells induce antitumor immunity. J Immunol 165:1705-1711
44. Gottfried E, Krieg R, Eichelberg C et al (2002) Characterization of cells prepared by dendritic cell-Tumor cell fusion. Cancer Immun 2:15
45. Greenberg PD (1991) Adoptive T cell therapy of tumors: Mechanisms operative in the recognition and elimination of tumor cells. Adv Immunol 49:281-355
46. Greenlee RT, Murray T, Bolden S, et al (2000) Cancer statistics, 2000. CA Cancer J Clin 50:7-33
47. Grohmann U, Bianchi R, Ayroldi E et al (1997) A tumor-Associated and self antigen peptide presented by dendritic cells may induce T cell anergy in vivo, but IL-12 can prevent or revert the anergic state. J Immunol 158:3593-3602
48. Guccion JG, Enzinger FM (1972) Malignant giant cell tumor of soft parts. An analysis of 32 cases. Cancer 29:1518-1529
49. Haenssle HA, Krause SW, Emmert S et al (2004) Hybrid cell vaccination in metastatic melanoma: Clinical and immunologic results of a phase I/II study. J Immunother 27:147-155
50. Hayashi T, Tanaka H, Tanaka J et al (2002) Immunogenicity and therapeutic efficacy of dendritictumor hybrid cells generated by electrofusion. Clin Immunol 104:14-20
51. Heath WR, Carbone FR (2001) Cross-presentation, dendritic cells, tolerance and immunity. Annu Rev Immunol 19:47-64
52. Heckelsmiller K, Beck S, Rall K et al (2002) Combined dendritic cell- And CpG oligonucleotidebased immune therapy cures large murine tumors that resist chemotherapy. Eur J Immunol 32:3235-3245
53. Hiraoka K, Yamamoto S, Otsuru S et al (2004) Enhanced tumor-specific long-Term immunity of hemagglutinating [correction of hemaggluttinating] virus of Japan-mediated dendritic celltumor fused cell vaccination by coadministration with CpG oligodeoxynucleotides. J Immunol 173:4297-4307
54. Holmes LM, Li J, Sticca RP et al (2001) A rapid, novel strategy to induce tumor cell-specific cytotoxic T lymphoctye responses using instant dentritomas. J Immunother 24:122-129
55. Homma S, Kikuchi T, Ishiji N et al (2005a) Cancer immunotherapy by fusions of dendritic and tumour cells and rh-IL-12. Eur J Clin Invest 35:279-286
56. Homma S, Komita H, Sagawa Y et al (2005b) Antitumour activity mediated by CD4+ cytotoxic T lymphocytes against MHC class II-negative mouse hepatocellular carcinoma induced by dendritic cell vaccine and interleukin-12. Immunology 115:451-461
57. Homma S, Matai K, Irie M et al (2003) Immunotherapy using fusions of autologous dendritic cells and tumor cells showed effective clinical response in a patient with advanced gastric carcinoma. J Gastroenterol 38:989-994
58. Homma S, Toda G, Gong J et al (2001) Preventive antitumor activity against hepatocellular carcinoma (HCC) induced by immunization with fusions of dendritic cells and HCC cells in mice. J Gastroenterol 36:764-771
59. Hsu FJ, Benike C, Fagnoni F et al (1996) Vaccination of patients with B-cell lymphoma using autologous antigen- pulsed dendritic cells. Nat Med 2:52-58
60. Hung K, Hayashi R, Lafond-Walker A et al (1998) The central role of CD4(+) T cells in the antitumor immune response. J Exp Med 188:2357-2368
61. Iinuma H, Okinaga K, Fukushima R et al (2004a) [Reduction of immunosuppression and shift to Th1 response by tumor-DC (dendritic cells) fusion vaccine]. Gan To Kagaku Ryoho 31: 1640-1642
62. Iinuma H, Okinaga K, Fukushima R et al (2006) Superior protective and therapeutic effects of IL-12 and IL-18 gene-Transduced dendritic neuroblastoma fusion cells on liver metastasis of murine neuroblastoma. J Immunol 176:3461-3469
63. Iinuma T, Homma S, Noda T et al (2004b) Prevention of gastrointestinal tumors based on adenomatous polyposis coli gene mutation by dendritic cell vaccine. J Clin Invest 113:1307-1317
64. Inaba K, Inaba M, Romani N et al (1992) Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med 176:1693-1702
65. Inaba K, Pack M, Inaba M et al (1997) High levels of a major histocompatibility complex II-self peptide complex on Dendritic cells from the T cell areas of lymph nodes. J Exp Med 186: 665-672
66. Inaba K, Witmer-Pack M, Inaba M et al (1994) The tissue distribution of the B7-2 costimulator in mice: Abundant expression on Dendritic cells in situ and during maturation in vitro. J Exp Med 180:1849-1860
67. Islam MQ, Meirelles Lda S, Nardi NB et al (2006) Polyethylene glycol-mediated fusion between primary mouse mesenchymal stem cells and mouse fibroblasts generates hybrid cells with increased proliferation and altered differentiation. Stem Cells Dev 15:905-919
68. Jantscheff P, Spagnoli G, Zajac P et al (2002) Cell fusion: An approach to generating constitutively proliferating human tumor antigen-presenting cells. Cancer Immunol Immunother 51:367-375
69. Jaroszeski MJ, Gilbert R, Fallon PG, et al (1994) Mechanically facilitated cell-cell electrofusion. Biophys J 67:1574-1581
70. Kaisho T, Akira S (2001) Dendritic-cell function in Toll-like receptor- And MyD88-knockout mice. Trends Immunol 22:78-83
71. Kao JY, Gong Y, Chen CM et al (2003) Tumor-derived TGF-beta reduces the efficacy of dendritic cell/tumor fusion vaccine. J Immunol 170:3806-3811
72. Kao JY, Zhang M, Chen CM, et al (2005) Superior efficacy of dendritic cell-Tumor fusion vaccine compared with tumor lysate-pulsed dendritic cell vaccine in colon cancer. Immunol Lett 101:154-159
73. Kikuchi T, Akasaki Y, Abe T et al (2004) Vaccination of glioma patients with fusions of dendritic and glioma cells and recombinant human interleukin 12. J Immunother 27:452-459
74. Kikuchi T, Akasaki Y, Irie M et al (2001) Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells. Cancer Immunol Immunother 50:337-344
75. Kinzler ER, Compton T (2005) Characterization of human cytomegalovirus glycoprotein-induced cell-cell fusion. J Virol 79:7827-7837
76. Kjaergaard J, Shimizu K, Shu S (2003) Electrofusion of syngeneic dendritic cells and tumor generates potent therapeutic vaccine. Cell Immunol 225:65-74
77. Knutton S (1979) Studies of membrane fusion. III. Fusion of erythrocytes with polyethylene glycol. J Cell Sci 36:61-72
78. Kohler G, Milstein C (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256:495-497
79. Kohler G, Milstein C (1976) Derivation of specific antibody-producing tissue culture and tumor lines by cell fusion. Eur J Immunol 6:511-519
80. Koido S, Hara E, Homma S et al (2005a) Dendritic cells fused with allogeneic colorectal cancer cell line present multiple colorectal cancer-specific antigens and induce antitumor immunity against autologous tumor cells. Clin Cancer Res 11:7891-7900
81. Koido S, Hara E, Homma S et al (2007a) Streptococcal preparation OK-432 promotes fusion efficiency and enhances induction of antigen-specific CTL by fusions of dendritic cells and colorectal cancer cells. J Immunol 178:613-622
82. Koido S, Hara E, Homma S et al (2007b) Synergistic induction of antigen-specific CTL by fusions of TLR-stimulated dendritic cells and heat-stressed tumor cells. J Immunol 179:4874-4883
83. Koido S, Hara E, Torii A et al (2005b) Induction of antigen-specific CD4- And CD8-mediated T-cell responses by fusions of autologous dendritic cells and metastatic colorectal cancer cells. Int J Cancer 117:587-595
84. Koido S, Homma S, Hara E et al (2008) In vitro generation of cytotoxic and regulatory T cells by fusions of human Dendritic cells and hepatocellular carcinoma cells. J Transl Med 6:51
85. Koido S, Kashiwaba M, Chen D et al (2000) Induction of antitumor immunity by vaccination of dendritic cells transfected with MUC1 RNA. J Immunol 165:5713-5719
86. Koido S, Ohana M, Liu C et al (2004) Dendritic cells fused with human cancer cells: Morphology, antigen expression, and T cell stimulation. Clin Immunol 113:261-269
87. Koido S, Tanaka Y, Chen D et al (2002) The kinetics of in vivo priming of CD4 and CD8 T cells by dendritic/tumor fusion cells in MUC1-Transgenic mice. J Immunol 168:2111-2117
88. Koido S, Tanaka Y, Tajiri H et al (2007c) Generation and functional assessment of antigen-specific T cells stimulated by fusions of dendritic cells and allogeneic breast cancer cells. Vaccine 25:2610-2619
89. Kokhaei P, Rezvany MR, Virving L et al (2003) Dendritic cells loaded with apoptotic tumour cells induce a stronger T-cell response than Dendritic cell-Tumour hybrids in B-CLL. Leukemia 17:894-899
90. Krause SW, Neumann C, Soruri A et al (2002) The treatment of patients with disseminated malignant melanoma by vaccination with autologous cell hybrids of tumor cells and dendritic cells. J Immunother 25:421-428
91. Kuby J (1992) Hybridoma and monoclonal antibody. In: Kuby J (ed) Immunology, vol 7. W.H. Freeman and Company, New York, NY, pp 141-156
92. Ladoire S, Arnould L, Apetoh L et al (2008) Pathologic complete response to neoadjuvant chemotherapy of breast carcinoma is associated with the disappearance of tumor-infiltrating foxp3+ regulatory T cells. Clin Cancer Res 14:2413-2420
93. Lamb RA, D K (2001) Paramyxoviridae: The viruses and their replication. Fields virology, 4th edn, 1305-1340
94. Lee WT, Shimizu K, Kuriyama H et al (2005) Tumor-dendritic cell fusion as a basis for cancer immunotherapy. Otolaryngol Head Neck Surg 132:755-764
95. Lee WT, Tan C, Koski G et al (2010) Immunotherapy using allogeneic squamous cell tumordendritic cell fusion hybrids. Head Neck in press
96. Lespagnard L, Mettens P, Verheyden AMet al (1998) Dendritic cells fused with mastocytoma cells elicit therapeutic antitumor immunity. Int J Cancer 76:250-258
97. Li J, Holmes LM, Franek KJ et al (2001) Purified hybrid cells from dendritic cell and tumor cell fusions are superior activators of antitumor immunity. Cancer Immunol Immunother 50:456-462
98. Linardakis E, Bateman A, Phan V et al (2002) Enhancing the efficacy of a weak allogeneic melanoma vaccine by viral fusogenic membrane glycoprotein-mediated tumor cell-Tumor cell fusion. Cancer Res 62:5495-5504
99. Lindner M, Schirrmacher V (2002) Tumour cell-dendritic cell fusion for cancer immunotherapy: Comparison of therapeutic efficiency of polyethylen-glycol versus electro-fusion protocols. Eur J Clin Invest 32:207-217
100. Liu Y, Zhang W, Chan T et al (2002) Engineered fusion hybrid vaccine of IL-4 genemodified myeloma and relative mature dendritic cells enhances antitumor immunity. Leuk Res 26:757-763
101. Loveland BE, Zhao A,White S et al (2006) Mannan-MUC1-pulsed dendritic cell immunotherapy: A phase I trial in patients with adenocarcinoma. Clin Cancer Res 12:869-877
102. Lundqvist A, Palmborg A, Bidla G et al (2004) Allogeneic tumor-dendritic cell fusion vaccines for generation of broad prostate cancer T-cell responses. Med Oncol 21:155-165
103. Margulies DH (2005) Monoclonal antibodies: Producing magic bullets by somatic cell hybridization. J Immunol 174:2451-2452
104. Marten A, Renoth S, Heinicke T et al (2003) Allogeneic dendritic cells fused with tumor cells: Preclinical results and outcome of a clinical phase I/II trial in patients with metastatic renal cell carcinoma. Hum Gene Ther 14:483-494
105. Marzo AL, Kinnear BF, Lake RA et al (2000) Tumor-specific CD4+ T cells have a major 'postlicensing' role in CTL mediated anti-Tumor immunity. J Immunol 165:6047-6055
106. Marzo AL, Lake RA, Robinson BW et al (1999) T-cell receptor transgenic analysis of tumor-specific CD8 and CD4 responses in the eradication of solid tumors. Cancer Res 59:1071-1079
107. Mayordomo JI, Zorina T, Storkus WJ et al (1995) Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat Med 1:1297-1302
108. McCune CS, O'Donnell RW, Horan PK et al (1982) Antitumor immunity induced by hybrid murine tumor cells: Requirements for optimal immunization. J Natl Cancer Inst 69:647-652
109. Menard C, Martin F, Apetoh L et al (2008) Cancer chemotherapy: Not only a direct cytotoxic effect, but also an adjuvant for antitumor immunity. Cancer Immunol Immunother 57:1579-1587
110. Michelsen KS, Aicher A, MohauptMet al (2001) The role of toll-like receptors (TLRs) in bacteriainduced maturation of murine dendritic cells (DCS). Peptidoglycan and lipoteichoic acid are inducers of DC maturation and require TLR2. J Biol Chem 276:25680-25686
111. Milstein C (1999) The hybridoma revolution: An offshoot of basic research. Bioessays 21:966-973
112. Mitchison NA (1990) An exact comparison between the efficiency of two- And three-cell-Type clusters in mediating helper activity. Eur J Immunol 20:699-702
113. Mountford AP, Anderson S, Wilson RA (1996) Induction of Th1 cell-mediated protective immunity to Schistosoma mansoni by co-Administration of larval antigens and IL-12 as an adjuvant. J Immunol 156:4739-4745
114. Mumberg D, Monach PA, Wanderling S et al (1999) CD4(+) T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-gamma. Proc Natl Acad Sci USA 96:8633-8638
115. Nakahara S, Tsunoda T, Baba T et al (2003) Dendritic cells stimulated with a bacterial product, OK-432, efficiently induce cytotoxic T lymphocytes specific to tumor rejection peptide. Cancer Res 63:4112-4118
116. Negrete OA, Levroney EL, Aguilar HC et al (2005) EphrinB2 is the entry receptor for Nipah virus, an emergent deadly paramyxovirus. Nature 436:401-405
117. Neil GA, Zimmermann U (1993) Electrofusion. Methods Enzymol 220:174-196
118. Nestle FO, Alijagic S, Gilliet M et al (1998) Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 4:328-332
119. O'Donnell RW, Horan PK, Minken TJ et al (1984) Antitumor immunity induced by hybrid tumor cells: Comparison between hybrids and the parental tumor. Cancer Res 44:487-492
120. Ogawa F, Iinuma H, Okinaga K (2004) Dendritic cell vaccine therapy by immunization with fusion cells of interleukin-2 gene-Transduced, spleen-derived dendritic cells and tumour cells. Scand J Immunol 59:432-439
121. Ogihara T, Iinuma H, Okinaga K (2004) Usefulness of immunomodulators for maturation of dendritic cells. Int J Oncol 25:453-459
122. Okada Y, Kim J, Maeda Y et al (1974) Specific movement of cell membranes fused with HVJ (Sendai virus). Proc Natl Acad Sci USA 71:2043-2047
123. Okada Y, Tadokoro J (1963) The distribution of cell fusion capacity among several cell strains or cells caused by HVJ. Exp Cell Res 32:417-430
124. Okada Y, Yamada K, Tadokoro J (1964) Effect of antiserum on the cell fusion reaction caused by HVJ. Virology 22:397-409
125. Okamoto M, Furuichi S, Nishioka Y et al (2004) Expression of toll-like receptor 4 on Dendritic cells is significant for anticancer effect of dendritic cell-based immunotherapy in combination with an active component of OK-432, a streptococcal preparation. Cancer Res 64:5461-5470
126. Orsini E, Guarini A, Chiaretti S et al (2003) The circulating dendritic cell compartment in patients with chronic lymphocytic leukemia is severely defective and unable to stimulate an effective T-cell response. Cancer Res 63:4497-4506
127. Ossendorp F, Mengede E, Camps M et al (1998) Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. J Exp Med 187:693-702
128. Paglia P, Chiodoni C, Rodolfo M et al (1996) Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J Exp Med 183:317-322
129. Pardoll D (2003) Does the immune system see tumors as foreign or self?. Annu Rev Immunol 21:807-839
130. Pare ME, Gauthier S, Landry S et al (2005) A new sensitive and quantitative HTLV-I-mediated cell fusion assay in T cells. Virology 338:309-322
131. Parkhurst MR, DePan C, Riley JP et al (2003) Hybrids of dendritic cells and tumor cells generated by electrofusion simultaneously present immunodominant epitopes from multiple human tumor-Associated antigens in the context of MHC class I and class II molecules. J Immunol 170:5317-5325
132. Phan V, Errington F, Cheong SC et al (2003) A new genetic method to generate and isolate small, short-lived but highly potent dendritic cell-Tumor cell hybrid vaccines. Nat Med 9:1215-1219
133. Plattet P, Rivals JP, Zuber B et al (2005) The fusion protein of wild-Type canine distemper virus is a major determinant of persistent infection. Virology 337:312-326
134. Primakoff P, Myles DG (2002) Penetration, adhesion, and fusion in mammalian sperm-egg interaction. Science 296:2183-2185
135. Qin Z, Blankenstein T (2000) CD4+ T cell - mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells. Immunity 12:677-686
136. Raje N, Hideshima T, Davies FE et al (2004) Tumour cell/dendritic cell fusions as a vaccination strategy for multiple myeloma. Br J Haematol 125:343-352
137. Ratta M, Fagnoni F, Curti A et al (2002) Dendritic cells are functionally defective in multiple myeloma: The role of interleukin-6. Blood 100:230-237
138. Ridge JP, Di Rosa F, Matzinger P (1998) A conditioned dendritic cell can be a temporal bridge between a CD4+ T- helper and a T-killer cell. Nature 393:474-478
139. Rodriguez-Tome P, Lijnzaad P (1999) The radiation hybrid database. Nucleic Acids Res 27: 115-118
140. Rosenberg SA (2004) Shedding light on tumor immunotherapy of cancer. New Engl J Med 350:461-1463
141. Rosenberg SA, Yang JC, Restifo NP (2004) Cancer Immunotherapy: Moving beyond current vaccines. Nat Med 10:909-915
142. Satthaporn S, Robins A, Vassanasiri W et al (2004) Dendritic cells are dysfunctional in patients with operable breast cancer. Cancer Immunol Immunother 53:510-518
143. Schnare M, Barton GM, Holt AC et al (2001) Toll-like receptors control activation of adaptive immune responses. Nature Immunol 2:947-950
144. Scott-Taylor TH, Pettengell R, Clarke I et al (2000) Human tumour and dendritic cell hybrids generated by electrofusion: Potential for cancer vaccines. Biochim Biophys Acta 1500:265-279
145. Sherman LA, Chattopadhyay S (1993) The molecular basis of allorecognition. Annu Rev Immunol 11:385-402
146. Shimizu K, Kuriyama H, Kjaergaard J et al (2004) Comparative analysis of antigen loading strategies of dendritic cells for tumor immunotherapy. J Immunother 27:265-272
147. Shortman K, HeathWR (2001) Immunity or tolerance?. That is the question for dendritic cells. Nat Immunol 2:988-989
148. Siders WM, Vergilis KL, Johnson C et al (2003) Induction of specific antitumor immunity in the mouse with the electrofusion product of tumor cells and dendritic cells. Mol Ther 7:498-505
149. Singer SJ, Nicolson GL (1972) The fluid mosaic model of the structure of cell membranes. Science 175:720-731
150. Specht JM, Wang G, Do MT et al (1997) Dendritic cells retrovirally transduced with a model antigen gene are therapeutically effective against established pulmonary metastases. J ExpMed 186:1213-1221
151. Steinman RM (1991) The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 9:271-296
152. Steinman RM (2001) Dendritic cells and the control of immunity: Enhancing the efficiency of antigen presentation. Mt Sinai J Med 68:106-166
153. Steinman RM, Swanson J (1995) The endocytic activity of dendritic cells. J ExpMed 182:283-288
154. Stolzing A, Hescheler J, Sethe S (2007) Fusion and regenerative therapies: Is immortality really recessive?. Rejuvenation Res 10:571-586
155. Suzuki T, Fukuhara T, TanakaMet al (2005) Vaccination of dendritic cells loaded with interleukin-12-secreting cancer cells augments in vivo antitumor immunity: Characteristics of syngeneic and allogeneic antigen-presenting cell cancer hybrid cells. Clin Cancer Res 11:58-66
156. Takeda A, Homma S, Okamoto T et al (2003) Immature dendritic cell/tumor cell fusions induce potent antitumour immunity. Eur J Clin Invest 33:897-904
157. Tamai H,Watanabe S, Zheng R et al (2008) Effective treatment of spontaneous metastases derived from a poorly immunogenic murine mammary carcinoma by combined dendritic-Tumor hybrid vaccination and adoptive transfer of sensitized T cells. Clin Immunol 127:66-77
158. Tanaka H, Shimizu K, Hayashi T et al (2002) Therapeutic immune response induced by electrofusion of dendritic and tumor cells. Cell Immunol 220:1-12
159. Tanaka Y, Koido S, Chen D et al (2001) Vaccination with allogeneic dendritic cells fused to carcinoma cells induces antitumor immunity in MUC1 transgenic mice. Clin Immunol 101:192-200
160. Tanaka Y, Koido S, Xia J et al (2004) Development of antigen-specific CD8+ CTL in MHC class I-deficient mice through CD4 to CD8 conversion. J Immunol 172:7848-7858
161. Tang CK, Lodding J, Minigo G et al (2007) Mannan-mediated gene delivery for cancer immunotherapy. Immunology 120:325-335
162. Thery C, Amigorena S (2001) The cell biology of antigen presentation in Dendritic cells. Curr Opin Immunol 13:45-51
163. Trefzer U, Herberth G, Wohlan K et al (2005) Tumour-dendritic hybrid cell vaccination for the treatment of patients with malignant melanoma: Immunological effects and clinical results. Vaccine 23:2367-2373
164. Trevor KT, Cover C, Ruiz YW et al (2004) Generation of dendritic cell-Tumor cell hybrids by electrofusion for clinical vaccine application. Cancer Immunol Immunother 53:705-714
165. Vasir B, Wu Z, Crawford K et al (2008) Fusions of dendritic cells with breast carcinoma stimulate the expansion of regulatory T cells while concomitant exposure to IL-12, CpG oligodeoxynucleotides, and anti-CD3/CD28 promotes the expansion of activated tumor reactive cells. J Immunol 181:808-821
166. Walden P (2000) Hybrid cell vaccination for cancer immunotherapy. Adv Exp Med Biol 465:347-354
167. Wang J, Saffold S, Cao X et al (1998) Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-Tumor fusion vaccines. J Immunol 161:5516-5524
168. Watts C (2004) The exogenous pathway for antigen presentation on major histocompatibility complex class II and CD1 molecules. Nat Immunol 5:685-692
169. Wolkers MC, Brouwenstijn N, Bakker AH et al (2004) Antigen bias in T cell cross-priming. Science 304:1314-1317
170. Xia D, Chan T, Xiang J (2005) Dendritic cell/myeloma hybrid vaccine. Methods Mol Med 113:225-233
171. Xia D, Li F, Xiang J (2004) Engineered fusion hybrid vaccine of IL-18 gene-modified tumor cells and dendritic cells induces enhanced antitumor immunity. Cancer Biother Radiopharm 19:322-330
172. Xia J, Tanaka Y, Koido S et al (2003) Prevention of spontaneous breast carcinoma by prophylactic vaccination with dendritic/tumor fusion cells. J Immunol 170:1980-1986
173. Yamanaka R, Homma J, Yajima N et al (2005) Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: Results of a clinical phase I/II trial. Clin Cancer Res 11:4160-4167
174. Yasuda T, Kamigaki T, Kawasaki K et al (2007) Superior anti-Tumor protection and therapeutic efficacy of vaccination with allogeneic and semiallogeneic dendritic cell/tumor cell fusion hybrids for murine colon adenocarcinoma. Cancer Immunol Immunother 56:1025-1036
175. Young JW, Inaba K (1996) Dendritic cells as adjuvants for class I major histocompatibility complex-restricted antitumor immunity. J Exp Med 183:7-11
176. Young JW, Koulova L, Soergel SA et al (1992) The B7/BB1 antigen provides one of several costimulatory signals for the activation of CD4+ T lymphocytes by human blood dendritic cells in vitro. J Clin Invest 90:229-237
177. Zhang HM, Zhang LW, Liu WC et al (2006) Comparative analysis of DC fused with tumor cells or transfected with tumor total RNA as potential cancer vaccines against hepatocellular carcinoma. Cytotherapy 8:580-588
178. Zhang JK, Li J, Zhang J et al (2003) Antitumor immunopreventive and immunotherapeutic effect in mice induced by hybrid vaccine of dendritic cells and hepatocarcinoma in vivo. World J Gastroenterol 9:479-484
179. Zhang M, Berndt BE, Chen JJ et al (2008) Expression of a soluble TGF-beta receptor by tumor cells enhances dendritic cell/tumor fusion vaccine efficacy. J Immunol 181:3690-3697
180. Zheng R, Cohen PA, Paustian CA et al (2008) Paired toll-like receptor agonists enhance vaccine therapy through induction of interleukin-12. Cancer Res 68:4045-4049
181. Zhou J, Weng D, Zhou F et al (2009) Patient-derived renal cell carcinoma cells fused with allogeneic dendritic cells elicit anti-Tumor activity: In vitro results and clinical responses. Cancer Immunol Immunother 58:1587-1597
182. Zou W (2005) Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 5:263-274
183. Zou W (2006) Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 6:295-307